About the Authors

Victoria K. Snowdon

Contributed equally to this work with: Victoria K. Snowdon, Neil J. Lachlan

Affiliation MRC Centre for Inflammation Research, University of Edinburgh, Edinburgh, United Kingdom

Neil J. Lachlan

Contributed equally to this work with: Victoria K. Snowdon, Neil J. Lachlan

Affiliation MRC Centre for Inflammation Research, University of Edinburgh, Edinburgh, United Kingdom

Anna M. Hoy

Affiliation MRC Centre for Inflammation Research, University of Edinburgh, Edinburgh, United Kingdom

Patrick W. F. Hadoke

Affiliation British Heart Foundation/University of Edinburgh Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom

Scott I. Semple

Affiliations British Heart Foundation/University of Edinburgh Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom, Clinical Research Imaging Centre, University of Edinburgh, Edinburgh, United Kingdom

Dilip Patel

Affiliation Department of Radiology, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom

Will Mungall

Affiliation Biological Services, University of Edinburgh, Edinburgh, United Kingdom

Timothy J. Kendall

Affiliation MRC Centre for Inflammation Research, University of Edinburgh, Edinburgh, United Kingdom

Adrian Thomson

Affiliation British Heart Foundation/University of Edinburgh Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom

Ross J. Lennen

Affiliation British Heart Foundation/University of Edinburgh Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom

Maurits A. Jansen

Affiliation British Heart Foundation/University of Edinburgh Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom

Carmel M. Moran

Affiliation British Heart Foundation/University of Edinburgh Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom

Antonella Pellicoro

Affiliation MRC Centre for Inflammation Research, University of Edinburgh, Edinburgh, United Kingdom

Prakash Ramachandran

Affiliation MRC Centre for Inflammation Research, University of Edinburgh, Edinburgh, United Kingdom

Isaac Shaw

Affiliation MRC Centre for Inflammation Research, University of Edinburgh, Edinburgh, United Kingdom

Rebecca L. Aucott

Affiliation MRC Centre for Inflammation Research, University of Edinburgh, Edinburgh, United Kingdom

Thomas Severin

Affiliation Novartis Pharma, Basel, Switzerland

Rajnish Saini

Affiliation Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States of America

Judy Pak

Affiliation Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States of America

Denise Yates

Affiliation Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, United States of America

Neelesh Dongre

Affiliation Novartis Pharma, Basel, Switzerland

Jeremy S. Duffield

Affiliation Division of Nephrology and Lung Biology, University of Washington, Seattle, Washington, United States of America

David J. Webb

Affiliation British Heart Foundation/University of Edinburgh Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom

John P. Iredale

Affiliation MRC Centre for Inflammation Research, University of Edinburgh, Edinburgh, United Kingdom

Peter C. Hayes

Affiliation MRC Centre for Inflammation Research, University of Edinburgh, Edinburgh, United Kingdom

Jonathan A. Fallowfield

Jonathan.Fallowfield@ed.ac.uk

Affiliation MRC Centre for Inflammation Research, University of Edinburgh, Edinburgh, United Kingdom

Competing Interests

PCH has received consultancy fees from Novartis and GORE. JAF has received consultancy fees from Merck and Novartis and research grant funding from GlaxoSmithKline. TS, JP, DY and ND are currently employees of Novartis and own either Novartis stocks or shares. TS, RS, JP, DY, and ND contributed to the Phase 2 trial of Serelaxin as Novartis associates but played no role in the independent preclinical research. RS is currently an employee of GlaxoSmithKline. DJW is a member of a Data Safety Monitoring Board for AbbVie for a phase 3 trial with atrasentan in renal disease (institutional) and a non-executive Board member of the Medicines and Healthcare products Regulatory Agency. DJW's research is supported by BHF, MRC and Wellcome Trust. JSD owns Biogen, Vertex, Regulus and BMS stock. JSD has patents for therapies to treat acute kidney injury.

Author Contributions

Conceptualization: JAF PCH JPI DJW TS JP ND. Data curation: SIS DP. Formal analysis: SIS DP TJK JAF AMH VKS PWFH NJL DY. Funding acquisition: JAF VKS TS. Investigation: VKS NJL PCH AMH PWFH WM JAF SIS DP PR AP TJK IS AT RJL RLA JSD. Methodology: JAF VKS NJL PCH SIS DP PWFH RJL MAJ AT CMM TS JP ND RS DY. Project administration: JAF PCH SIS DJW TS. Supervision: JAF JPI TS RS. Validation: DP TJK RS JP DY. Visualization: AMH JAF VKS NJL PWFH. Writing – original draft: JAF VKS AMH NJL. Writing – review & editing: JPI JSD DJW MAJ PWFH TS DY SIS DP WM TJK AT RJL CMM AP PR IS RLA RS JP ND PCH.